1. Transgenic mouse overexpressing the Akt reduced the volume of infarct area after middle cerebral artery occlusion
- Author
-
Mitsuyo Maeda, Michinari Muraoka, Sumiko Kiryu-Seo, Hiroshi Kiyama, Masamitsu Ishii, and Norihiro Ohba
- Subjects
Genetically modified mouse ,medicine.medical_specialty ,Ratón ,Transgene ,Ischemia ,Mice, Transgenic ,Protein Serine-Threonine Kinases ,Biology ,Severity of Illness Index ,Neuroprotection ,Mice ,In vivo ,Proto-Oncogene Proteins ,Internal medicine ,medicine ,Animals ,Protein kinase B ,General Neuroscience ,Infarction, Middle Cerebral Artery ,Cerebral Infarction ,Genetic Therapy ,medicine.disease ,Recombinant Proteins ,Genetic Enhancement ,Treatment Outcome ,Endocrinology ,Feasibility Studies ,Endothelin receptor ,Proto-Oncogene Proteins c-akt - Abstract
Transgenic mouse lines expressing the active form Akt gene under the control of the damage-induced neuronal endopeptidase (DINE) promoter were made from three different founder mice, and its neuroprotective potential against ischemic brain damage was investigated. Twenty-four hours after middle cerebral artery occlusion, two DINE-Akt-transgenic mouse lines displayed reductions of the infarcted area by 35% compared to the wild-type littermate. RT-PCR assays showed a high level of transgene in response to ischemic brain damage in these lines. These results suggest that the DINE promoter is a useful promoter, which responds to neuronal insults and that the Akt-induced neuroprotective effect against ischemic damage is potent in vivo.
- Published
- 2004
- Full Text
- View/download PDF